Certolizumab Pegol in Crohn's Disease Management: A Multicentric Brazilian Observational Study
| Autor: | Thaisa Kowalski Furlan, Marcello Imbrizi, Daniela Magro, Paula C. Senger de Castro, Rodrigo Bremer Nones, Eron Fabio Miranda, Paulo G. Kotze |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Journal of Coloproctology, Vol 44, Iss 03, Pp e187-e195 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2237-9363 2317-6423 |
| DOI: | 10.1055/s-0044-1789223 |
| Popis: | Introduction and Objectives Certolizumab Pegol (CZP) is an anti-TNF agent approved in Brazil for Crohn's disease (CD). There is a lack of data in Brazil and Latin America detailing real-world experiences with CZP. The primary objective was clinical remission in weeks 26 and 54. The secondary endpoints were clinical response in weeks 26 and 54, endoscopic remission, biological switch rates, rates of CD-related surgery, persistence with treatment over time, and adverse events. Remission and clinical response were defined as HBI ≤4 and ≥3 points reduction of HBI, respectively. Endoscopic remission was defined as the complete healing of the intestinal mucosa. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|